PBF-680
- Generic Name
- PBF-680
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 107
- Registration Number
- NCT03774290
- Locations
- 🇪🇸
Unitat de Pneumologia Experimental, Barcelona, Spain
A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 8
- Registration Number
- NCT02635945
- Locations
- 🇪🇸
Unitat de Pneumologia Experimental, Barcelona, Spain
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-680 After Multiple Oral Doses"
- First Posted Date
- 2014-08-05
- Last Posted Date
- 2016-03-08
- Lead Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Target Recruit Count
- 40
- Registration Number
- NCT02208973
- Locations
- 🇪🇸
CIM-Sant Pau - IIB Sant Pau, HSCSP, Barcelona, Spain
🇪🇸Palobiofarma S.L. (molecule owner), Mataró, Barcelona, Spain
"First-in-human" Study To Assess the Safety and Tolerability of PBF-680 in Male Healthy Volunteers
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2016-03-08
- Lead Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Target Recruit Count
- 32
- Registration Number
- NCT01845181
- Locations
- 🇪🇸
CIM-Sant Pau. Hospital de la Santa Creu i Sant Pau, Barcelona, Catalunya, Spain
🇪🇸Palobiofarma S.L. (molecule owner), Mataró, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath